Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 10;18(6):5793–5800. doi: 10.3892/ol.2019.10975

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Yoshida et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Immunohistochemical assessment of p21 in HSC-3 ×enografts in response to celecoxib with/without LPS-treatment. (A) Representative microphotographs of p21-immunostained tumor sections in each group. Scale bar, 50 µm. (B) Percentage of p21-positive tumor cells. Each column represents the mean number of p21-positive cells ± standard deviation. The celecoxib-treated and LPS + celecoxib-treated groups had significantly increased levels of p21 compared with the control and LPS-treated groups. The levels of p21 in the LPS + celecoxib-treated group were significantly decreased compared with those in the celecoxib-treated group. **P<0.01 vs. control or LPS-treated group. LPS, lipopolysaccharide.